Evidence map›Paper›PMID 38761030›Full record

ArticleESC heart failure2024

The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure.

Valeria Visco, Cristina Esposito, Antonella Rispoli, Paola Di Pietro, Carmine Izzo, Francesco Loria, Daniele Di Napoli, Nicola Virtuoso, Alessia Bramanti, Michele Manzo and 2 more

Abstract read
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Cardiovascular Nursing in Rehabilitative Cardiology: A Review.Journal of cardiovascular development and disease · 2025
    Review
  4. GRK2 and Mitochondrial Dynamics in Cardiovascular Health and Disease.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Valeria ViscoDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.ORCID 0000-0002-2197-5355
Cristina EspositoCardiology Unit, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona' Salerno, Salerno, Italy.
Antonella RispoliDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.
Paola Di PietroDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.
Carmine IzzoDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.
Francesco LoriaDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.
Daniele Di NapoliDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.
Nicola VirtuosoCardiology Unit, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona' Salerno, Salerno, Italy.
Alessia BramantiDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.
Michele ManzoCardiology Unit, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona' Salerno, Salerno, Italy.
Carmine VecchioneDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.ORCID 0000-0002-2473-4565
Michele CiccarelliDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via Salvador Allende, 84081, Baronissi, Salerno, Italy.ORCID 0000-0003-2379-1960

Funding

Innovation Agreement D.M. 02.8.2019 Life Sciences-MISESOLOMAX SociaLNetwOrk of MedicAlEXperiences F/260007/05/X51-CUP: B49J21031700008
6 · The paper itself

Abstract

aimsWe report the results of a real-world study based on heart failure (HF) patients' continuous remote monitoring strategy using the CardioMEMS system to assess the impact of this device on healthcare outcomes, costs, and patients' management and quality of life. METHODS AND

resultsWe enrolled seven patients (69.00 ± 4.88 years; 71.43% men) with HF, implanted with CardioMEMS, and daily remote monitored to optimize both tailored adjustments of home therapy and/or hospital infusions of levosimendan. We recorded clinical, pharmacological, biochemical, and echocardiographic parameters and data on hospitalizations, emergency room access, visits, and costs. Following the implantation of CardioMEMS, we observed a 50% reduction in the total number of hospitalizations and a 68.7% reduction in the number of days in the hospital. Accordingly, improved patient quality of life was recorded with EQ-5D (pre 58.57 ± 10.29 vs. 1 year post 84.29 ± 19.02, P = 0.008). Echocardiographic data show a statistically significant improvement in both systolic pulmonary artery pressure (47.86 ± 8.67 vs. 35.14 ± 9.34, P = 0.022) and E/e' (19.33 ± 5.04 vs. 12.58 ± 3.53, P = 0.023). The Quantikine® HS High-Sensitivity Kit determined elevated interleukin-6 values at enrolment in all patients, with a statistically significant reduction after 6 months (P = 0.0211). From an economic point of view, the net savings, including the cost of CardioMEMS, were on average €1580 per patient during the entire period of observation, while the analysis performed 12 months after the implant vs. 12 months before showed a net saving of €860 per patient. The ad hoc analysis performed on the levosimendan infusions resulted in 315 days of hospital avoidance and a saving of €205 158 for the seven patients enrolled during the observation period.

conclusionsThis innovative strategy prevents unplanned access to the hospital and contributes to the efficient use of healthcare facilities, human resources, and costs.

Indexed as

Cardiotonic AgentsHeart FailureQuality of LifeSimendanAgedFemaleFollow-Up StudiesHumansHydrazonesMaleMiddle AgedPyridazinesTreatment OutcomeCardiotonic AgentsHydrazonesPyridazinesSimendanCardioMEMSHeart failureLevosimendanTelemonitoring

Identifiers

PMID38761030
PMCPMC11424304

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.